German Antitrust Clearance Received for Esperion Therapeutics Acquisition
ESPR has more than doubled off its 52-week low of $0.949.
Summary
Esperion Therapeutics received German antitrust clearance for its acquisition by Essence Parent, advancing the $3.16 per share cash merger towards its scheduled shareholder vote on July 8, 2026.
Key Events · M&A and Partnerships · ESPR
-
German Antitrust Clearance
The Bundeskartellamt (German antitrust authority) has cleared the proposed acquisition of Esperion Therapeutics by Essence Parent Inc., effective June 2, 2026.
-
Merger Progress
This clearance satisfies a key condition for the merger, which was initially announced on May 1, 2026, for $3.16 per share in cash plus CVRs.
-
Remaining Conditions
The merger remains subject to other closing conditions, including the expiration of HSR Act waiting periods and approval by Esperion's stockholders at a special meeting scheduled for July 8, 2026.
Analysis · ESPR · Life Sciences
This 8-K announces that Esperion Therapeutics has received antitrust clearance from the Bundeskartellamt for its acquisition by Essence Parent Inc. This fulfills a key condition for the merger, moving the transaction closer to completion. The acquisition, valued at $3.16 per share in cash plus CVRs, is still subject to other conditions, including U.S. antitrust review and shareholder approval, which is scheduled for July 8, 2026.
At the time of this filing, ESPR was trading at $3.14 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $808.3M. The 52-week trading range was $0.95 to $4.18. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.